159 related articles for article (PubMed ID: 23007681)
1. Pharmacokinetic and safety evaluation of the use of ciprofloxacin on an isoniazid-rifampicin regimen in rabbits.
Padilha EC; Pires RV; Filho MA; de Pontes Machado DV; Baldan HM; Davanço MG; Campos ML; Brunetti IL; Peccinini RG
Biopharm Drug Dispos; 2012 Dec; 33(9):501-9. PubMed ID: 23007681
[TBL] [Abstract][Full Text] [Related]
2. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
[TBL] [Abstract][Full Text] [Related]
3. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
[TBL] [Abstract][Full Text] [Related]
4. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
[TBL] [Abstract][Full Text] [Related]
5. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.
Mariappan TT; Singh S
Int J Tuberc Lung Dis; 2003 Aug; 7(8):797-803. PubMed ID: 12921157
[TBL] [Abstract][Full Text] [Related]
6. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
[TBL] [Abstract][Full Text] [Related]
7. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
Avachat AM; Bhise SB
Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
[TBL] [Abstract][Full Text] [Related]
9. Effect of different oral doses of isoniazid-rifampicin in rats.
Rana SV; Pal R; Vaiphie K; Singh K
Mol Cell Biochem; 2006 Sep; 289(1-2):39-47. PubMed ID: 16583132
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
12. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
Kimerling ME; Phillips P; Patterson P; Hall M; Robinson CA; Dunlap NE
Chest; 1998 May; 113(5):1178-83. PubMed ID: 9596291
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
Roy V; Tekur U; Chopra K
Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
[TBL] [Abstract][Full Text] [Related]
15. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
16. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
17. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Grosset J; Truffot-Pernot C; Lacroix C; Ji B
Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
[TBL] [Abstract][Full Text] [Related]
18. Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats.
Naji KM; Al-Khatib BY; Al-Haj NS; D'souza MR
BMC Pharmacol Toxicol; 2021 Jul; 22(1):39. PubMed ID: 34217369
[TBL] [Abstract][Full Text] [Related]
19. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic interference between rifampicin and isoniazid.
Llorens J; Serrano RJ; Sanchez R
Chemotherapy; 1978; 24(2):97-103. PubMed ID: 620612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]